19,460 reports of this reaction
6.7% of all NATALIZUMAB reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 19,460 FDA adverse event reports linking NATALIZUMAB to FATIGUE. This represents approximately 6.7% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among NATALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 19,460 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 6.7% of all adverse event reports for NATALIZUMAB, making it one of the most commonly reported side effect.
If you experience fatigue while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.